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Abstract
Cytotoxic T lymphocyte (CTL) responses targeting specific HIV proteins, in particular Gag, have been associated with relative
control of viral replication in vivo. However, Gag-specific CTL can also be detected in individuals who do not control the
virus and it remains thus unclear how Gag-specific CTL may mediate the beneficial effects in some individuals but not in
others. Here, we used a 10mer peptide set spanning HIV Gag-p24 to determine immunogen-specific T-cell responses and to
assess functional properties including functional avidity and cross-reactivity in 25 HIV-1 controllers and 25 non-controllers
without protective HLA class I alleles. Our data challenge the common belief that Gag-specific T cell responses dominate the
virus-specific immunity exclusively in HIV-1 controllers as both groups mounted responses of comparable breadths and
magnitudes against the p24 sequence. However, responses in controllers reacted to lower antigen concentrations and
recognized more epitope variants than responses in non-controllers. These cross-sectional data, largely independent of
particular HLA genetics and generated using direct ex-vivo samples thus identify T cell responses of high functional avidity
and with broad variant reactivity as potential functional immune correlates of relative HIV control.
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Introduction
Several studies in cohorts of clade B and clade C-infected
individuals have shown that cytotoxic T-cell (CTL) responses
against HIV-1 Gag correlate with relative control of HIV-1
[1,2,3,4]. The rapid re-presentation of epitopes derived from the
Gag proteins contained in the infecting viral particles and
structural constraints of the Gag protein that complicate CTL
escape have been suggested as possible mechanisms that lend Gag-
specific CTL responses this superior effectiveness in controlling
HIV-1 [5,6]. However, in all studies reporting beneficial effects of
Gag-specific responses, some HIV-1-infected non-controllers
mount detectable responses against Gag as well, raising the
question as to why these individuals are unable to control their
viral replication. A possible answer to this question is that
functional characteristics [7,8,9], including functional avidity and
variant cross-reactivity are distorted in the CTL population in
HIV non-controllers. However, some of these characteristics may
not be captured reliably when using some standard in vitro antigen
test sets and assay systems [10,11].
In the present study, we analyzed HIV Gag-p24 specific T cell
responsesinHIV-1controllersandnon-controllersusing18merand
10 mer peptide sets to compare relative response rates using either
longer or shorter test peptides and to determine the functional
avidity of these responses as well as their ability to react with
naturally occurring sequence variants. Furthermore, the data also
allowedto assess whether the most conserved regions within p24are
differentially targeted by HIV-1 controllers and non-controllers in
order to provide in vitro relevance for vaccine approaches focusing
on such conserved elements (CE) in the viral genome [12,13].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29717Although responses to Gag p24 were of comparable breadth
and magnitude in HIV-1 controllers and non-controllers when
using the 10 mer peptide set, significantly higher avidity responses
were seen in controllers, who also showed broader epitope variant
cross-reactivity than non-controllers. The data suggest that the
maintenance of high avidity responses with broad variant
recognition potential is a potential hallmark of controlled HIV-1
infection; a finding that may have important implications in the
development of preventative as well as therapeutic vaccine
strategies.
Results
Gag p24 specific T cell responses in controllers and non-
controllers are significantly increased when using 10 mer
peptides sets
Chronically HIV-1 infected individuals with controlled HIV
infection (n=25; median viral load 810 RNA copies/ml and
median CD4 cell count 642 cells/mm
3) and non-controlled viral
replication (n=25; viral load median viral load 200,000 RNA
copies/ml and median CD4 cell counts 98 cells/mm
3) were
recruited from the HIV Unit in Hospital Germans Trias i Pujol,
Badalona, Spain. The study was approved by the Institutional
Review Board of the Hospital Germans Trias i Pujol and all
individuals provided written informed consent. Median age of
individuals was slightly higher for the non-controllers group
compared to controllers (44 years-old (24–55) vs 38 years-old (26–
56), p=0.04) but individuals did not significantly differ in time
since HIV diagnosis (p=0.07) (Table 1). The participants were
mostly of Caucasian ethnicity (79% Caucasian, 17% Hispanic, 2%
African and 2% Asian) and the ethnic origin did not differ between
the two groups. HLA diversity was heterogeneous in both groups
and individuals expressing HLA-B27, HLA-B57, or HLA-B58
were intentionally excluded from the cohort to avoid bias due to
the presence of dominant Gag p24 CTL epitopes restricted by
these alleles and to overcome the limitations of past studies in
which these alleles were highly over-represented (Table S1).
In a first step, the distribution of total HIV-1-specific T-cell
responses using a 18 mer overlapping peptide (OLP) set covering
the full HIV-1 proteome was assessed in the 50 individuals
included. The majority of responses were directed against OLP
located in the HIV-1 Gag, Pol and Nef proteins with a relative
dominance of Gag/p24 in HIV-1 controllers (p=0.0336 for Gag,
p=0.0486 for Gag p24), These data confirmed the expected
distribution of responses from earlier reports in HIV-1 controllers
even though the present cohort was smaller and did not include
individuals expressing known protective HLA class I alleles [4,14].
Of note, the peptide concentrations used were relatively high
(14 ug/ml), and in our hands saturating [15], to avoid missing
responses due to suboptimal peptide concentrations.
To increase the sensitivity of the assay and to discern potential
functional differences of Gag responses in non-controllers unable
to mediate relative viral control in these subjects, all individuals
were tested against a set of 223 10 mer peptides (overlapping by 9
residues) spanning the group M Center-of-Tree (COT-M) Gag
p24 sequence (Figure S1). Significantly more responses were
identified by using the 10 mers in both groups (Figure 1A,B;
p=0.0002 for controllers, p=0.0006 non-controllers). 20 of the 25
individuals in each group showed an increase in the detected
responses with the 10 mer test set; while only 3 had equivalent
breadth and 2 individuals in each group had one response less
compared to the 18 mer peptides. Controllers and non-controllers
showed a 2–3-fold increase of their responses which abolished the
broader response rates seen in controllers when using the 18 mer
peptides (p=0.4260). Responses detected with the 10 mer peptide
set were of comparable magnitude in the two groups, both in
terms of total magnitude (median 4,250 vs. 2,600 SFC/10
6 PBMC
in controllers and non-controllers, respectively; p=0.6004,
Figure 1C) and the average magnitude of individual responses
(median 614 vs. 657 SFC/10
6PBMC, p=0.9178, Figure 1D).
Table 1. Demographic and main clinical characteristics of the 25 controllers and 25 non-controllers tested
a.
C (n=25) NC (n=25) P value
Age, years 38 (26.2–55.7) 44.5 (24.3–54.8) 0.04
Time since HIV-1 diagnosis (years) 9.3 (3.5–26.3) 15.9 (1.5–23.3) 0.07
Gender (Female/Male) F 40%/M 60% F 40%/M 60%
HIV risk group
Heterosexual
b 6 (24%) 10 (40%) 0.36
Men who have sex with men
b 8 (32%) 4 (16%) 0.32
Injecting drug users
b 7 (28%) 9 (36%) 0.76
Other
b 4 (16%) 2 (8%) 0.66
Last CD4+ T cell counts (cells/mm
3) 642 (434–1114) 98 (11–361) ,0.001
% CD4 cells 32 (16–50) 9 (1–27) ,0.001
Last HIV-1 RNA levels (copies/ml) 810 (UD
C-10,000) 200,000 (52,000–1,200,000) ,0.001
HLA alleles representation
HLA-A (n=24 alleles) 20 alleles 15 alleles
HLA-B (n=34 alleles) 27 alleles 17 alleles
HLA-C (n=20 alleles) 17 alleles 15 alleles
aData are expressed as median (min-max range),
bn, (%),
cUD: undetectable viremia (,49 copies/ml).
doi:10.1371/journal.pone.0029717.t001
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readily detectable in HIV-1 non-controllers when using a sensitive
10 mer peptide set and that they are unlikely to represent spurious,
nonspecific reactivities. The data also show that using 18 mer
peptides may potentially miss up to 2/3 of responses, al least in
some of the HIV non-controllers and the antigen (i.e. p24) tested
here.
Responses in HIV-1 controllers are of higher functional
avidity than in non-controllers and mediate better
variant recognition
Data from animal studies and our own analyses in HCV
infection suggest that T cell responses of high functional avidity are
superior in mediating viral control [3,16,17,18]. We thus tested
whether HIV-1 controllers and non-controllers differed in the
overall functional avidity of their responses. Based on cell
availability, the functional avidity was determined for a total of
474 individual positive responses (219 in controllers and 255 in
non-controllers). Controllers indeed showed responses of higher
functional avidity (median 6,110 ng/ml, range 0.05–7.6610
7)
compared to non-controllers (median of 13,548 ng/ml, range
0.64–4610
9; p=0.0101, Figure 2A). This difference was more
pronounced when the analyses was limited to the 52 10 mer-
specific responses that were titrated in both groups (6,998 ng/ml
vs. 46,637 ng/ml, respectively; p=0.0173, Figure 2B) While it is
possible that even within one 10 mer peptide more than one
epitope could be located (i.e. 9 mer optimal epitopes) and that
10 mer responses could be due to presentation of different epitopes
on different HLA alleles, the HLA representation between
controllers and non-controllers was similar (particularly because
HLA-B57, 58, B27 expressing individuals were excluded).
Therefore, it is likely that the same epitope in the same HLA
context was being targeted in most of the cases included in the
matched analysis and that differential allele-effects would not have
impacted the comparison between the two groups.
As high avidity responses may be more prone to react with
sequence variants in their cognate epitopes, they may provide a
crucial advantage in the control of highly variable pathogens such
as HIV and HCV [7,17]. To address whether high avidity
responses in HIV controllers would indeed react with more
epitope variants, naturally occurring sequence variants were tested
for cross-recognition in all 50 subjects using a set of 88 additional
Figure 1. Increased detection of Gag p24 specific responses using a 10 mer peptide set. IFN-c ELISpot responses against Gag p24 elicited
either by consensus B overlapping 18 mer or COT-M 10 mer peptide sets in 25 HIV-1 controllers (A) and 25 HIV-1 non-controllers (B) P-values reflect
the increase in median breadth of responses when using 10 mer peptide sets instead the 18 mer peptides (two-tailed Wilcoxon matched paired test).
Total magnitude of responses (C) and average magnitude of responses (D) to COT-M Gag p24 10 mer peptides are shown for 25 controllers and 25
non-controllers, respectively. Lines represent median values and indicated p values are based on Mann-Whitney t-tests.
doi:10.1371/journal.pone.0029717.g001
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29717Figure 2. High avidity responses are enriched in HIV-1 controllers and mediate superior variant recognition. (A) Comparison of
functional avidity of all COT-M Gag p24 responses titrated in controllers (n=219 responses) vs. non-controllers (n=255 responses) (B) Comparison of
functional avidities limited to responses targeting the same 10 mer OLP in the two groups (n=52 responses, Wilcoxon). In (C) the total breadth
(number) of the response to the tested COT-M Gag p24 variant peptides (n=88) is indicated for controllers and non-controllers. (D) Shows the
percentage of variant peptides that were reactive when the COT-M sequence elicited a response (‘‘cross-reactive responses’’) and (E) indicates
responses to variant peptides for which the COT-M sequence did not elicit a response (‘‘gained responses’’). The association between functional
avidity and cross-reactivity is shown in (F) where responses with functional avidities in either the first quartile of all titrated responses
CTL Avidity and Cross-Reactivity in HIV Control
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these 88 variants was 2-fold greater in controllers (median of 4
responses; range 2–9) than in HIV-1 non-controllers (median 2
responses, range 0–16, p=0.0236, Figure 2C). In particular,
controllers showed responses to both the wild-type and variant
peptides in half of the cases where a COT-M and a variant peptide
was tested (50%) while only 31% in HIV-1 non-controllers reacted
to variants (Figure 2D). While this did not reach statistical
significance, controllers reacted with significantly more variant
peptides for which the COT-M sequence did not elicit a response
(median of 2 additional responses by inclusion of variants, range
0–7) than the non-controllers (median 1, range 0–5; p=0.0351;
Figure 2E). The average magnitude of the variant-specific
responses was comparable between controllers (median of 742
SFC/10
6PBMC, range 90–3,073) and non-controllers (median
473 SFC/10
6PBMC, range 60–2,707; p=0.5605, data not shown)
indicating that cross-reactive responses in HIV non-controllers
were robust, when present.
In order to directly test whether functional avidity was related to
the ability to recognize peptide variants, titrated responses were
grouped into high, intermediate and low avidity responses and
their variant recognition potentials were compared. Indeed,
responses with functional avidities in the first quartile of all
titrated responses (SD50%,1,401 ng/ml) showed cross-reactivity
with their variants in 67% of all cases, whereas fewer (48% and
33%) responses of intermediate or low functional avidity were
cross-reactive with their variants, respectively (Figure 2F).
Collectively, the data demonstrate that high avidity responses
were more prevalent in HIV-1 controllers and that these responses
mediate superior variant recognition than responses of low
functional avidity.
Conserved regions in Gag p24, containing HLA-B14, -B27
and B57 restricted, protective CTL epitopes are
frequently targeted by HIV-1 controllers that do not
express protective HLA alleles
The high degree of sequence conservation in HIV Gag p24
makes this protein an interesting vaccine component and many
vaccine immunogen designs indeed include Gag p24 [12,19,20]. A
recently developed immunogen sequence is based on a strong
focus on the most conserved elements (CE) within Gag p24,
excluding variable segments that could contain potential decoy
epitopes that may divert the host T cell response towards less
valuable targets [13]. These CE were defined as sequence stretches
of at least 12 amino acids in length that contain only amino acids
residues with at least 98% sequence conservation across all
available independent group M sequences [13]. Gag p24 contains
7 of such CE segments, ranging from 12 to 24 amino acids in
length and corresponding to a total of 124 residues (Figure S1).
To validate this immunnogen concept, we stratified the T cell data
from the 50 controllers and non-controllers based on the location
of the targeted 10 mer, i.e. whether they were located within or
outside of these conserved elements. Both groups showed
comparable breadth and magnitudes of total CE-specific responses
(Figure 3A). Also, controllers reacted with significantly more
epitope variants located in CE regions than non-controllers
(median of 2 responses in controllers vs. 1 response in non-
controllers, p=0.0145, data not shown). Of note, these differences
were not due to a suboptimal match between test peptide
sequences and autologous viral HIV-1 sequences in the non-
controllers as their dominant autologous p24 sequence was in all
cases clade B and mostly (99%) represented by the test peptides
(Figure S2).
Of interest, there were three CE that were recognized by at least
50% more controllers compared to non-controllers (referred to as
CE #4, #5, #6), suggesting that these may be preferential targets
in HIV-1 controllers (Figure 3B). In fact, HIV-1 controllers
mounted significantly more responses to at least one of these three
CE than did non-controllers (p=0.0006; Figure 3C) and showed
a trend towards these being responses of higher functional avidity,
even though only a fraction of the overall data points were
included in this comparison (median 7,189 ng/ml, range 0.99–
2.5610
7 vs. median of 17,058 ng/ml, range 16.28–2.62610
7;
p=0.0666, data not shown). In addition, the total magnitude of
the responses to CE #4+5+6 showed a statistically significant
correlation with HIV-1 viral load (r=20.5, p=0.0002 by
Spearman’s rank, Figure 3D) across all 50 subjects, suggesting
that stronger responses to these three regions may mediate better
control of viral replication.
Interestingly, these 3 regions included the well-characterized
HLA-B57 restricted TW10 epitope (in CE #4), the HLA-B27
restricted KK10 epitope (in CE #5), and the HLA-B14 restricted
DA9 epitope (in CE #6), all of which have been previously
associated with containment of in vivo HIV-1 replication
[21,22,23,24]. However, as the cohort did not contain any
HLA-B57+ and -B27+ individuals and only 2 subjects expressed
HLA-B14, the data indicate that mounting responses to these
regions is effective even if these protective responses are being
restricted by HLA class I molecules different from the originally
described restricting HLA molecules [25,26]. Indeed, the HLA
class I allele representation of CE #4, #5o r#6 responders was
heterogeneous and not limited to individuals with a few shared
HLA alleles (Table S1) indicating that the CE regions represent a
very rich set of epitopes that are not being blocked from
presentation in natural chronic infection and that are able to be
recognized in a wide HLA class I context.
Discussion
Together, our data strongly suggest that the presence of
responses of high functional avidity and with broad variant
recognition ability is a potential hallmark of controlled HIV-1
infection. To the best of our knowledge, this is the first
demonstration of a direct link between high avidity T cell
responses, broad variant recognition and in vivo HIV-1 control
using ex-vivo blood samples from a cohort with largely unbiased
HLA genotypes. Our data also support that standard approaches
using 15–20 mer overlapping peptides underestimate the breadth
of responses to HIV Gag p24 significantly. While similar findings
have been reported in earlier studies, none has addressed this in a
systematic way and including a comparably extensive avidity
determination as in the present study. More importantly though,
since HIV non-controllers profited the most from using a more
sensitive peptide set, the data have also important implication for
our understanding of HIV immunopathogenesis and vaccine
immunogen design: It is not that HIV-1 non-controllers would not
mount Gag-specific T-cell responses; rather, they may have either
(SD50%,1,401 ng/ml) or the second or third quartile (SD50% 1,401–71,594 ng/ml) or the fourth quartile (SD50%.71,594 ng/ml) were defined as
‘‘high’’, ‘‘intermediate’’ and low’’ avidity responses. The percentage of variants that elicited a response was compared between the three groups
(Fishers Exact Test).
doi:10.1371/journal.pone.0029717.g002
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originally high functional avidity responses that were lost over the
course of HIV-1 infection. This latter interpretation would be in
line with results from longitudinal analyses in individuals followed
from acute infection time points [27,28]. Although these analyses
were based on fewer individuals and included many donors
expressing HLA-B27 and -B57 alleles, clonal exhaustion of high
avidity cells in the course of chronic HIV replication is certainly a
possible explanation why the HIV non-controllers in our study
showed responses of reduced functional avidity. On the other
hand, it is interesting to note that in a recent report by Berger et al,
high avidity responses were not only not restored upon HAART
initiation but were actually further diminished [7], suggesting that
possibly other factors than duration and extend of antigenimia
impact the measurable avidity of an epitope-specific T cell
population.
The wide spread and overlap in the avidity measurements
between responses among the two groups is probably the biggest
challenge for this kind of study to conclusively demonstrate its
potential biological significance. Quite likely, inter-epitope and
inter-individual differences hamper a clearer observation. In
addition, given that different effector functions are subject to
variable activation thresholds [29], the inclusion of additional in
vitro read-outs could possibly provide a larger discrimination in
the minimal antigen amounts required for responses in HIV
controllers and non-controllers. Indeed, as limited effector
functions have been previously described for HIV-1 non-
controllers, one would expect additional reactivities to occur
preferentially in the controllers group. Despite the limitation of
assessing a single effector function (IFNc release) though, our
findings are supported by a number of previous studies in animal
models and in HIV and HCV infection that have assessed the
Figure 3. CE containing HLA-B14, -B27 and B57 restricted, protective CTL epitopes are predominantly targeted by HIV-1
controllers. (A) The total magnitude of responses to CE regions is compared between HIV controllers and non-controllers. (B) The frequency of
recognition of the 7 different CE is shown for 25 HIV-1 controllers (C) and 25 non-controllers (NC), respectively. CE regions targeted by at least 50%
more controllers than non-controllers are boxed and p-values indicated (T test). (C) Breadth of responses to the combination of CE 4+5+6 regions in
controllers vs. non-controllers is shown. Horizontal lines represent median values and Mann-Whitney t-test p value is shown. (D) Correlation between
the cumulative magnitude of responses to CE 4+5+6 and HIV viral loads in all 50 tested individuals is shown (Spearman’s rank test).
doi:10.1371/journal.pone.0029717.g003
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and variant recognition [17,30,31,32,33,34,35,36,37]. Moreover,
none of earlier studies in humans has been based on the extensive
number responses analyzed here (close to 500 titrated responses)
and most used either in vitro expanded short-term T cell lines or T
cell clones [17,32]. While analyzing the functional avidity in clonal
T cell populations allows eliminating some of the inherent
heterogeneity faced in cross-sectional, directly ex-vivo studies,
the in vitro selection and expansion of epitope-specific clones may
be biasing results too, as shown for HCV specific responses where
short-term culture consistently increased the functional avidity
compared to directly ex-vivo isolated cells [17]. On the other
hand, our data may be limited by the use of 10 mers instead of
optimal epitopes for the determination of functional avidity.
However, many optimally defined epitopes in Gag are 10 mers
and, it has frequently been shown that 9 and 10 mers can have
similar SD50%. In fact, in many cases, the definition of optimal
epitopes is more driven by the shorter length of 9 mers rather than
a substantially lower SD50% [26], suggesting that the 10 mer
approach used here is an acceptable approximation to avoid biases
or missing responses by alternative optimal epitope or 9-mer
approaches.
In order to control for some of the heterogeneity in our data set,
we also compared SD50% between matched responses targeting
the same 10 mer peptide in the controller and non-controller
group. This indeed enhanced the otherwise modest differences in
SD50% between the two groups considerably and was statistically
significant despite the much smaller number of responses
analyzed. The limited difference in SD50% for the overall analysis
may also be due to variable activation thresholds for specific CTL
effector functions [29]. As such, the observed difference in the
SD50% necessary for IFNc release may not be directly relevant
for the improved viral control in vivo but may still reflect a more
avid and thus more effective interaction between the CTL and the
antigen-presenting cell, regardless of the ensuing cascade of
effector function(s).
As mentioned above, high functional avidity may also render
CTL more prone to immune senescence or clonal exhaustion,
particularly in individuals with suboptimal control of viral
replication. The data from cleared and chronic HCV infection
support this idea as only HCV clearers seem to maintain responses
of high functional avidity in the absence of possible sources of
residual antigen [17]. Thus, while high avidity responses may win
out during the induction phase of the virus-specific T cell response,
these cells may be preferentially lost over time if viral antigenemia
cannot be controlled sufficiently well [28,38]. Whether such losses
of high avidity responses correspond to changes in the clonal
composition of the CD8 T cell response or to a gradual decrease in
their functional avidity due to altered cell reactivity/signaling
needs to be further addressed in different clinical settings, as the
existing data discussing the ‘cause/effect’ quandary are conflicting
and generally limited to responses restricted by few selected HLA
alleles [28,32,39,40,41,42].
Further studies will ideally also include other highly conserved
regions in the viral genome outside Gag p24, which may serve as
additional components of vaccine immunogens. Such extended
analyses would also increase the number of responses per
individual, which in the present study is relatively small given
that only a short segment of the entire viral proteome was
analyzed. Despite this focus on p24, our comparisons reached
statistical significance and compared well to the breadth of
responses reported in earlier studies looking at responses to the
entire HIV proteome or optimally defined HIV CTL epitopes
[4,14,15,25]. Together with the results here, these earlier analyses
also provide support that the detected responses are generally CD8
T-cell mediated, particularly when testing short 10 mer peptides
and that they are HIV-specific since testing with even optimally
defined short HIV-derived CTL epitopes did not readily elicit
responses in HIV negative individuals [15,25].
Given these considerations, our study suggests that HIV-1
controllers mount ex-vivo responses of significantly higher
functional avidity than HIV-1 non-controllers. Since the high
avidity responses were also more apt to react with epitope variants,
their induction by a future HIV-1 vaccine may be crucial to
prevent rapid viral escape from the vaccine induced immune
response. Finally, as the data presented here confirm findings in
HCV infection, they strongly suggest that the ability to maintain T
cell responses of high functional avidity is a more general hallmark
of effective immune control of infections with highly variable
pathogens.
Materials and Methods
Synthetic peptides set
An overlapping peptide set of 223 peptides of 10 amino acids in
length (overlapping by 9 residues) spanning the entire group M
Center-of-Tree (COT-M) Gag p24 sequence was synthesized
using 9-Fluorenylmethyloxycarbonyl (Fmoc)- chemistry. Addition-
al 88 10-mer peptides were generated to cover the most frequently
occurring variants in the 7 most conserved (CE) regions. We also
included a previously described overlapping peptide (410 18 mers
OLP) set spanning the entire viral proteome [4,14] based on the
2001 consensus-B sequence (http://hiv-web.lanl.gov/content/hiv-
db/CONSENSUS/M_GROUP/Consensus.html). Peptides were
18 mers varying from 15–20 amino acids in length and
overlapping by 10 amino acids, designed using the PeptGen
algorithm at the Los Alamos HIV database (http://www.hiv.lanl.
gov/content/sequence/PEPTGEN/peptgen.html).
IFN-c ELISpot assay
PBMC were separated from whole blood within 4 h of
venopuncture and used directly for the IFN-c ELISpot. Each
COT-M Gag p24 peptide was tested individually and added at a
final concentration of 14 mg/ml. For all assays, between 75,000–
100,000 PBMC per well were added in 140 ul of R10 96-well
polyvinylidene plates (Millipore, Bedford, MA). The IFN-c
Mabtech kit was used following manufacturer instructions. In
parallel, CTL responses to the clade B full proteome were assessed
using the 18 mer peptide set in a previously described optimized
peptide matrix, followed by deconvolution of reactive pools and
reconfirmation of each response at a single peptide level on the
following day and tested at the same concentration of 14 mg/ml
[14]. The number of spots was counted using a ‘‘CTL ELISpot
Reader Unit’’ and the magnitude of responses was expressed as
spot forming cells (SFC) per million input cells. The threshold for
positive responses was defined as at least 5 spots per well and
responses exceeding the ‘‘mean number of spots in negative
control wells plus 3 standard deviations of the negative control
wells’’ and ‘‘three times the mean of negative control wells’’,
whichever was higher. As a conservative approach and not to
overestimate the breadth of responses, positive responses to 3
consecutive 10 mers in the COT-M Gag p24 peptide set were
counted as 1 unique response. Similarly, reactivity to 2 consecutive
18 mer OLP was counted as 1 response. The highest magnitude of
the sequential responses was taken as the magnitude for each
identified response.
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The functional avidity of responses was determined by
performing serial 10-fold limiting peptide dilutions ranging from
100 mg/ml to 10 pg/ml using the 10 mer peptide set; in duplicate
whenever enough PBMC were available. Half-maximal stimula-
tory antigen doses (SD50%) were calculated as the peptide
concentration needed to achieve a half-maximal number of spots
in the ELISpot assay calculated by a sigmoidal dose response curve
fit using GraphPad Prism4.
Gag p24 sequencing
Viral RNA was extracted from 1 millilitre of plasma spun at
25000 rpm for 1 hour (QIAamp Viral RNA Kit
TM, QIAGEN,
Valencia, CA). The whole Gag region was reverse-transcribed and
amplified in a One-Step reaction (SuperScriptH III One-Step RT-
PCR System with PlatinumH Taq High Fidelity, Invitrogen,
Carlsbad, CA) under the following conditions: 30 min at 52uC for
the reverse transcription step; 2 min at 94uC; followed by 35 cycles
at 94uC during 30 sec, 58uC during 30 sec and 68uC during
2 min; followed by a final extension step at 68uC during 5 min.
Primers used for the RT-PCR were: Gag U761 (HXB2: 761–778)
59-TTT GAC TAG CGG AGG CTA G-39 and Gag D2397
(HXB2: 2397–2376) 59-CCC CTA TCA TTT TTG GTT TCC
A-39. One microliter of the RT-PCR product was subsequently
used as a template for a nested PCR (PlatinumH Taq DNA
Polymerase High Fidelity, Invitrogen, Carlsbad, CA), using
primers p24 U1070 (HXB2: 1070–1088) 59-TAA AAG ACA
CCA AGG AAG CT and p24 D2063 (HXB2: 2063–2044) 59-
TCT TTC ATT TGG TGT CCT TC-39. PCR cycling
conditions were: 2 min at 94uC; followed by 35 cycles at 94uC
during 30 sec, 54uC during 30 sec and 68uC during 2 min;
followed by a final extension step at 68uC during 5 min. The final
PCR products were column-purified (QIAquick PCR Purification
Kit, QIAGEN, Valencia, CA) and sequenced bidirectionally.
Sequences were assembled using SequencherH 4.10.1 (Genecodes
Corp. MI). Assembled sequences were codon-aligned using the
Hidden Markov Model implemented in the HIValign tool (www.
lanl.hiv.gov). Autologous Gag p24 bulk sequences were obtained
for 22 of the 25 HIV-1 non-controllers included in our study.
Sequences were submitted to Genbank; accession numbers BCN-
NC-1.sqn BCN-NC-1 JQ246370-246391.
Statistical analyses
All values are presented as median values unless otherwise
stated. GraphPad Prism version 4.0 for Windows (San Diego, CA)
was used to compare response rates in both groups and subgroup
analyses. Mann-Whitney test and Wilcoxon matched paired test
were used for unpaired and paired comparisons, respectively.
Spearman rank correlation was used to assess association.
Supporting Information
Figure S1 COT-M Gag-p24 sequence and location of CE
segments. The Center-of-tree (COT) M sequence is indicated
for entire Gag p24. The location of known optimally-defined CTL
epitopes listed at the Los Alamos HIV database, are indicated
above the protein sequence while the shaded boxes beneath
indicate the 7 CE segments and variant (down) residues included
in this study.
(TIF)
Figure S2 Autologous Gag-p24 CE sequences in 21 HIV-
1 non-controllers. Shaded boxes indicate the 7 CE sequences
located within in p24 with variant residues included (separated by
‘‘/’’. The amino acid sequences of autologous Gag p24 bulk
sequences obtained from 22 HIV non-controllers are shown.
(TIF)
Table S1 HLA genotypes of the 25 controllers and 25
non-controllers tested.
(DOC)
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